10-K: Jaguar Health Reports $54.4M Loss, Secures $18M Upfront Capital

Jaguar Health, Inc. reported a net comprehensive loss of $54.4 million for 2025, an increase from $39.0 million in 2024, while securing $18 million in upfront non-dilutive capital from a US licensing agreement for Mytesi and Canalevia-CA1.

Summary

• Net comprehensive loss increased to $54.4 million in 2025 from $39.0 million in 2024.
• Total revenue decreased slightly to $11.5 million in 2025 from $11.7 million in 2024.
• Research and development (R&D) expenses increased by 50.9% to $25.0 million in 2025, primarily due to advanced clinical programs and contract manufacturing.
• Sales and marketing (S&M) expenses increased by 20.1% to $9.2 million in 2025, driven by the Gelclair sales team.
• General and administrative (G&A) expenses increased by 14.2% to $18.6 million in 2025, mainly due to higher legal fees and public company expenses.
• An impairment loss of $800,000 was recognized on in-process R&D (IPR&D) assets due to delays in IBS and PEDS programs.
• Secured $16 million in upfront non-dilutive capital in January 2026 from a US licensing agreement with Future Pak, with an additional $2 million due upon post-closing conditions.
• Future Pak became the exclusive marketer for Mytesi and Canalevia-CA1 in the US.
• Crofelemer powder for oral solution is in advanced clinical development for Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF), with Orphan Drug Designations from FDA and EMA.
• Presented groundbreaking results from pediatric IF patients with MVID and SBS-IF, showing parenteral support (PS) reductions of up to 37% and 15.6% respectively.
• Launched Gelclair in October 2024 for oral mucositis in the US.
• Magdalena Biosciences, a joint venture, is focused on developing plant-based medicines for mental health, including ADHD.
• Received conditional FDA approval for Canalevia-CA1 for chemotherapy-induced diarrhea (CID) in dogs in December 2021.
• NP-300, a second-generation anti-secretory drug, is in preclinical development for cholera, with potential for a tropical disease priority review voucher (TDPRV).
• The company has an accumulated deficit of $399.9 million and a total stockholders' deficit of $18.7 million as of December 31, 2025.
• Received a Nasdaq delisting notification on March 5, 2026, due to bid price falling below $1.00, and the company is appealing.
• Issued pre-funded common stock purchase warrants for 1,609,372 shares to Iliad in December 2025.
• Declared a special one-time dividend of Series O Preferred Stock on February 18, 2026, which will convert into common stock and cause significant dilution.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Jaguar Health, marked by increasing losses, significant debt, and a Nasdaq delisting notice, despite some positive clinical developments and a recent capital infusion. The long-term viability remains highly dependent on successful product commercialization and securing substantial additional financing.

Positives

• Secured $16 million in upfront non-dilutive capital in January 2026 from a US licensing agreement with Future Pak for Mytesi and Canalevia-CA1, with an additional $2 million upon post-closing conditions and up to $20 million in milestone payments.
• Crofelemer powder for oral solution is in advanced clinical development for ultrarare pediatric disorder MVID and SBS-IF, with near-term New Drug Application (NDA) opportunity for MVID.
• Crofelemer received Orphan Drug Designation (ODD) from the FDA for MVID in February 2023 and from the EMA in October 2022.
• Crofelemer received ODD from the EMA for SBS in December 2021 and from the FDA in August 2017.
• FDA activated Napo's Investigational New Drug (IND) application for crofelemer powder for oral solution for MVID in August 2023.
• Groundbreaking results from pediatric IF patients with MVID and SBS-IF showed significant reductions in parenteral support (PS) (up to 37% for MVID, up to 15.6% for SBS-IF).
• Launched Gelclair, an FDA-approved oral mucositis prescription product, in the US in October 2024, providing rapid and long-lasting pain relief without numbing or stinging.
• Magdalena Biosciences, a joint venture with Filament Health, is focused on developing novel plant-based prescription medicines for mental health indications like ADHD.
• Received conditional FDA approval for Canalevia-CA1 for chemotherapy-induced diarrhea (CID) in dogs in December 2021, with MUMS designation.
• NP-300 program is being pursued with the potential targeted incentive of a tropical disease priority review voucher (TDPRV) from the FDA, which has sold for $60 million to $350 million in past transactions.
• Napo holds approximately 195 patents for crofelemer, with most expiring between 2027-2031, providing a strong IP position.
• Established a second crofelemer manufacturing site with Indena S.p.A. in Italy, which completed validation activities in January 2023.
• Mytesi is reimbursed by almost all commercial and Medicare insurance plans and covered by Medicaid in all 50 states.

Negatives

• Net comprehensive loss increased significantly from $39.0 million in 2024 to $54.4 million in 2025.
• Total revenue decreased slightly from $11.7 million in 2024 to $11.5 million in 2025.
• Accumulated deficit of $399.9 million and total stockholders' deficit of $18.7 million as of December 31, 2025.
• Cash balance of $968,000 as of December 31, 2025, is insufficient to fund operations for one year from the filing date.
• R&D expenses increased by 50.9%, and S&M expenses increased by 20.1%.
• An impairment loss of $800,000 was recognized on IPR&D assets due to delays in IBS and PEDS programs.
• The OnTarget Phase 3 clinical trial for crofelemer in all solid tumor types did not meet its primary endpoint.
• The company is substantially dependent on the success of its new licensee, Woodward Specialty LLC, for Mytesi and Canalevia-CA1, and future revenue will solely depend on the manufacturing and supply agreement with Woodward.
• Mytesi faces significant competition from other pharmaceutical companies.
• Gelclair faces significant competition from established treatments and larger pharmaceutical companies.
• Dependent on two suppliers for the raw material (CPL) for crofelemer, and termination of either contract could disrupt product development.
• Dependent on third-party contract manufacturers for API and finished products, and issues could delay plans.
• Royalty interests require minimum royalty payments starting July 2026, totaling approximately $27.0 million, even if product sales are insufficient, straining cash resources.
• Received a Nasdaq delisting notification on March 5, 2026, due to bid price non-compliance, and the company is appealing.
• The potential issuance of a large number of common stock shares upon conversion of Series O Preferred Stock may have a negative effect on the trading price and cause significant dilution.
• The company may find it more difficult to raise additional equity capital while Series O Preferred Stock is outstanding.
• The company may not have sufficient authorized shares of common stock to satisfy the full conversion of Series O Preferred Stock if the conversion price is reduced, requiring stockholder approval for an increase or reverse stock split.

Risks

• Limited operating history and expectation of further losses, with inability to achieve or sustain profitability.
• Need to raise substantial additional capital in the future, with uncertainty of availability on acceptable terms, potentially forcing delays or termination of product development programs.
• Substantial dependence on the success of new licensee Woodward Specialty LLC for Mytesi and Canalevia-CA1, with future revenue solely dependent on the manufacturing and supply agreement.
• Uncertainty of receiving necessary approvals for planned Mytesi or Canalevia-CA1 follow-on indications or successful commercialization.
• Uncertainty in the commercialization success of Gelclair due to competitive market.
• Significant competition for Mytesi from other pharmaceutical companies for both approved and planned indications.
• Inability to obtain timely regulatory approval for existing or future human or animal prescription drug product candidates.
• Even with regulatory approval, products may not achieve market acceptance.
• Dependence on two suppliers for raw material (CPL) for Mytesi and Canalevia-CA1, with risk of disruption if contracts terminate.
• Dependence on third-party contract manufacturers for API and finished products, with risk of disruption.
• Obligations to Streeterville Capital, LLC are secured by NP-300 assets, risking foreclosure upon default.
• Royalty interests require minimum royalty payments starting July 2026, totaling approximately $27.0 million, even if sales are insufficient, straining cash resources.
• Uncertainty of patent strategy effectiveness against competition.
• Risk of patent protection reduction or elimination due to non-compliance with procedural requirements.
• Potential legal proceedings alleging intellectual property infringement, which would be costly and time-consuming.
• Proprietary position depends on botanical guidance and method-of-use patents, which do not prevent competitors from using identical products for other uses.
• Failure to meet Nasdaq Capital Market continued listing requirements could result in delisting.
• If shares become subject to penny stock rules, trading would become more difficult.
• Stock price volatility related or unrelated to operations, potentially leading to substantial losses for purchasers.
• Dilution from exercises of outstanding options and warrants, and issuances of securities pursuant to ATM Agreement and/or stockholder rights plan.
• Issuance of additional common stock and other securities to repay debt would dilute proportionate ownership and voting rights and could negatively impact stock price.
• Series O Preferred Stock is not freely transferable, providing limited liquidity.
• Potential issuance of a large number of common stock shares upon conversion of Series O Preferred Stock may negatively affect trading price and cause significant dilutive effect.
• Holders of Eligible Warrants will not receive the Preferred Stock Dividend unless and until exercise, and rights cease upon transfer.
• Unanticipated post-approval safety or efficacy concerns for human and animal products could harm business and reputation.
• Increased exposure to product liability claims due to potential future federal and state legislation allowing non-economic damages for animal harm.
• Inability to obtain timely renewal of conditional approval for Canalevia-CA1 or full regulatory approval.
• Risk of losing MUMS designation benefits for Canalevia-CA1.
• Market for human and animal products may be smaller than anticipated.
• Limited or terminated insurance coverage for Mytesi or lack of coverage for follow-on indications.
• Challenges obtaining favorable reimbursement and insurance coverage for Gelclair.
• Future acquisitions may increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.
• Operating in developing countries with potentially unstable political and economic climates.
• Changing political environment in the US could adversely affect business and financial performance.
• Fluctuations in foreign currency exchange rates.
• Global trade compliance laws and anti-bribery regulations (e.g., FCPA) could adversely impact business.
• Competition from larger pharmaceutical companies in the gastrointestinal segment.
• Failure in information technology systems, including cyber-attacks, could disrupt operations.
• Global macroeconomic conditions (inflation, interest rates, geopolitical events) may negatively affect the company.
• Misuse or extra-label use of approved products may harm reputation or result in damages.
• Legislative or regulatory reforms in animal health may increase costs and delays.
• Risk that regulatory bodies may disagree with the company's interpretation of non-prescription product regulation.
• Ongoing obligations and continued regulatory review for approved products may result in significant additional expenses.
• Failure to report adverse medical events could lead to sanctions.
• Commercial supply regulated by FDA, failure to gain agreement could affect supply.
• Conditional approval for drug candidates is renewable annually for five years and may be withdrawn.

Future Outlook

The company plans to submit the final clinical study report for the OnTarget trial and additional details of the responder analysis in breast cancer patients, along with a patient survey, to the FDA in the second half of 2026. Approval of crofelemer powder for oral solution for MVID in the US is pursued following the completion of the pivotal pediatric MVID trial. Napo Therapeutics plans to pursue PRIME designation from the EMA, and Napo plans to pursue Breakthrough Therapy Designation (BTD) from the FDA for crofelemer powder for oral solution for Intestinal Failure. The NP-300 program is being pursued with the potential incentive of a tropical disease priority review voucher from the FDA, and the next stage of clinical development for cholera-related diarrhea will be initiated when resources are available. The company expects general and administrative expenses to decrease in the near term as focus shifts to pipeline development and market access expansion for IF programs. Expenditures are expected to increase as product and pipeline development continues, and the company will continue to seek additional capital through various financing methods.

Management Comments

• Jaguar is poised to realize the opportunities for the commercialization of crofelemer powder for oral solution for our IF programs from MVID and SBS-IF.
• Our management team has significant experience in gastrointestinal product development.
• We believe this approach will lead to better long-term outcomes for our products in development.
• We expect that NP-300 could be significantly less expensive and would support development efforts to receive a tropical disease priority review voucher (TDPRV) from the FDA for an indication of the symptomatic treatment of diarrhea from acute infections such as cholera.
• We believe NP-300 represents a long-term pipeline opportunity as a second-generation anti-secretory agent, on a global basis, for multiple gastrointestinal diseases, especially in resource-constrained countries where the cost of goods is a factor.
• Management continues to assess the evolving implications of the IRA on pricing, reimbursement, and research incentives.
• Management continues to monitor timelines closely to address any risks that could impact timely project completion and future operations.
• Management believes this infusion [of $18M] improves our liquidity, but the Company still needs additional funding.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry, particularly in rare diseases and supportive care, is characterized by high R&D costs and intense competition from larger players. The focus on orphan drug designations for MVID and SBS-IF aligns with a trend of companies targeting niche markets with significant unmet needs and regulatory incentives. The licensing agreement with Future Pak for Mytesi and Canalevia-CA1 reflects a common strategy for smaller biopharmaceutical companies to leverage larger partners' commercial capabilities for established products, allowing them to focus R&D on pipeline assets. The pursuit of a tropical disease priority review voucher for NP-300 is a recognized incentive mechanism in the industry to encourage development for neglected diseases. The increasing focus on ESG matters and AI systems also reflects broader industry trends impacting corporate responsibility and operational efficiency.

Comparison to Industry Standards

• The global SBS market exceeded $568 million in 2019 and is expected to reach $4.6 billion by 2027, indicating a significant growth opportunity for crofelemer powder for oral solution.
• The estimated global market size for MVID therapies is in the range of $50 million to $100 million, based on market research with key opinion leaders (KOLs) and payers.
• Comparable supportive care (i.e., CINV) product sales were ~$620 million in 2013, with the global CINV market projected to reach $2.7 billion by 2022, suggesting a substantial market for CTD indications.
• Most IBS products have an estimated revenue potential of greater than $1.0 billion.
• Priority review vouchers have sold for prices ranging from $60 million to $350 million in past transactions by other companies, such as AbbVie Inc. buying one for $350 million from United Therapeutics Corp in 2015 and BioMarin selling one to Sanofi and Regeneron for $67.5 million in 2014.
• Takeda Pharmaceuticals commercializes GATTEX (teduglutide) for SBS, and Zorbtive is another recombinant human growth hormone for SBS. Crofelemer powder for oral solution is positioned as a 'paradigm-shifting first-in-class novel therapy' that does not require intestinal adaptation and can be used in patients ineligible for GLP-2 therapies.
• No FDA-approved drugs specifically act as anti-secretory drugs to improve stool consistency for infectious diarrhea, making NP-300 a potential first-of-its-kind.

Corporate Governance

Legal Proceedings

• A former employee filed a complaint against the company with the American Arbitration Association (AAA) on February 3, 2026. The company believes the lawsuit is without merit and intends to defend itself vigorously.

Related Party Transactions

• Board of Directors cash compensation amounted to approximately $431,000 for the year ended December 31, 2025, and $442,000 for 2024.
• Certain Insiders (including the CEO, CFO, and board members) participated in the March 2025 Convertible Notes Financing, purchasing $535,000 aggregate principal amount of notes and receiving warrants.
• The company entered into various exchange agreements and financing arrangements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, both affiliated with Chicago Venture Partners, L.P., an institutional investor.

Stakeholder Impact

• Shareholders: Potential significant dilution from future equity issuances and conversion of Series O Preferred Stock; risk of investment loss due to recurring losses and going concern doubt; stock price volatility; potential delisting from Nasdaq.
• Employees: Potential impact on recruitment and retention due to stock price volatility and financial uncertainty; potential for disciplinary action up to termination for insider trading violations.
• Customers (Mytesi, Canalevia-CA1): Continued availability of products through new licensing agreement with Future Pak; potential for expanded access to crofelemer for MVID/SBS-IF patients through expedited regulatory pathways and early access programs.
• Cancer Patients (Gelclair, CTD): Access to Gelclair for oral mucositis; potential for crofelemer for prophylaxis of cancer therapy-related diarrhea in breast cancer patients.
• Pediatric MVID/SBS-IF Patients: Potential for a paradigm-shifting therapy (crofelemer powder for oral solution) to reduce parenteral support needs.
• Creditors (Iliad, Uptown, Streeterville): Debt restructuring and exchange agreements impact repayment terms and security interests; risk of foreclosure on NP-300 assets by Streeterville upon default.
• Suppliers: Dependence on two CPL suppliers and third-party contract manufacturers creates supply chain risk.

Next Steps

• Submit the final clinical study report (CSR) for the OnTarget trial and additional details of the responder analysis in breast cancer patients, along with a patient survey, to the FDA in the second half of 2026.
• Submit a protocol to the FDA for a pivotal treatment trial for metastatic breast cancer patients using crofelemer.
• Pursue approval of crofelemer powder for oral solution for MVID in the US following the completion of the pivotal pediatric MVID trial.
• Napo Therapeutics plans to pursue PRIME designation from the EMA for crofelemer powder for oral solution for IF.
• Napo plans to pursue Breakthrough Therapy Designation (BTD) from the FDA for crofelemer powder for oral solution for IF.
• Initiate the next stage of clinical development for cholera-related diarrhea (NP-300) when resources are available.
• Identify a partner to collaborate on EU approval for Canalevia for general diarrhea in dogs, maintain US availability for CID in dogs, and expand US indication to general diarrhea in dogs.
• Appeal the Nasdaq delisting notification.
• Continue to monitor performance with respect to Nasdaq listing standards and consider available options to resolve any deficiency.
• Continue to pursue all available avenues for financing and continuously assess capital structure and operational needs.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring and increasing net losses ($54.4 million in 2025), a substantial accumulated deficit ($399.9 million), and a critical cash balance ($968,000) insufficient to fund operations for the next year. The Nasdaq delisting notification further exacerbates liquidity and investor confidence issues. While the $18 million upfront capital from the Future Pak licensing agreement provides some immediate relief, it is explicitly stated as insufficient to fully alleviate going concern doubts. The potential for massive dilution from the conversion of Series O Preferred Stock and future debt-for-equity exchanges poses a significant risk to existing shareholders. Despite promising clinical developments in rare diseases, the company's precarious financial position and operational risks outweigh these long-term prospects, making it a high-risk investment.

Keywords

Jaguar Health, Napo Pharmaceuticals, Mytesi, Crofelemer, Canalevia-CA1, Gelclair, NP-300, Microvillus Inclusion Disease (MVID), Short Bowel Syndrome with Intestinal Failure (SBS-IF), Chemotherapy-Induced Diarrhea (CID), HIV/AIDS, Oral Mucositis, Orphan Drug Designation, FDA, EMA, Clinical Trials, Pharmaceutical, Biotechnology, Gastrointestinal, Rare Disease, Animal Health, Mental Health, Magdalena Biosciences, Capital Raise, Nasdaq Delisting, Royalty Interests, Pre-funded Warrants